165 related articles for article (PubMed ID: 38277467)
1. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD.
Seddighi S; Qi YA; Brown AL; Wilkins OG; Bereda C; Belair C; Zhang YJ; Prudencio M; Keuss MJ; Khandeshi A; Pickles S; Kargbo-Hill SE; Hawrot J; Ramos DM; Yuan H; Roberts J; Sacramento EK; Shah SI; Nalls MA; Colón-Mercado JM; Reyes JF; Ryan VH; Nelson MP; Cook CN; Li Z; Screven L; Kwan JY; Mehta PR; Zanovello M; Hallegger M; Shantaraman A; Ping L; Koike Y; Oskarsson B; Staff NP; Duong DM; Ahmed A; Secrier M; Ule J; Jacobson S; Reich DS; Rohrer JD; Malaspina A; Dickson DW; Glass JD; Ori A; Seyfried NT; Maragkakis M; Petrucelli L; Fratta P; Ward ME
Sci Transl Med; 2024 Feb; 16(734):eadg7162. PubMed ID: 38277467
[TBL] [Abstract][Full Text] [Related]
2. Mis-spliced transcripts generate
Seddighi S; Qi YA; Brown AL; Wilkins OG; Bereda C; Belair C; Zhang Y; Prudencio M; Keuss MJ; Khandeshi A; Pickles S; Hill SE; Hawrot J; Ramos DM; Yuan H; Roberts J; Kelmer Sacramento E; Shah SI; Nalls MA; Colon-Mercado J; Reyes JF; Ryan VH; Nelson MP; Cook C; Li Z; Screven L; Kwan JY; Shantaraman A; Ping L; Koike Y; Oskarsson B; Staff N; Duong DM; Ahmed A; Secrier M; Ule J; Jacobson S; Rohrer J; Malaspina A; Glass JD; Ori A; Seyfried NT; Maragkakis M; Petrucelli L; Fratta P; Ward ME
bioRxiv; 2023 Jan; ():. PubMed ID: 36747793
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of cryptic splicing associated with TDP-43 depletion.
Humphrey J; Emmett W; Fratta P; Isaacs AM; Plagnol V
BMC Med Genomics; 2017 May; 10(1):38. PubMed ID: 28549443
[TBL] [Abstract][Full Text] [Related]
4. Cryptic exon detection and transcriptomic changes revealed in single-nuclei RNA sequencing of C9ORF72 patients spanning the ALS-FTD spectrum.
Gittings LM; Alsop EB; Antone J; Singer M; Whitsett TG; Sattler R; Van Keuren-Jensen K
Acta Neuropathol; 2023 Sep; 146(3):433-450. PubMed ID: 37466726
[TBL] [Abstract][Full Text] [Related]
5. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.
Ma XR; Prudencio M; Koike Y; Vatsavayai SC; Kim G; Harbinski F; Briner A; Rodriguez CM; Guo C; Akiyama T; Schmidt HB; Cummings BB; Wyatt DW; Kurylo K; Miller G; Mekhoubad S; Sallee N; Mekonnen G; Ganser L; Rubien JD; Jansen-West K; Cook CN; Pickles S; Oskarsson B; Graff-Radford NR; Boeve BF; Knopman DS; Petersen RC; Dickson DW; Shorter J; Myong S; Green EM; Seeley WW; Petrucelli L; Gitler AD
Nature; 2022 Mar; 603(7899):124-130. PubMed ID: 35197626
[TBL] [Abstract][Full Text] [Related]
6. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.
Ling JP; Pletnikova O; Troncoso JC; Wong PC
Science; 2015 Aug; 349(6248):650-5. PubMed ID: 26250685
[TBL] [Abstract][Full Text] [Related]
7. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.
Irwin KE; Jasin P; Braunstein KE; Sinha IR; Garret MA; Bowden KD; Chang K; Troncoso JC; Moghekar A; Oh ES; Raitcheva D; Bartlett D; Miller T; Berry JD; Traynor BJ; Ling JP; Wong PC
Nat Med; 2024 Feb; 30(2):382-393. PubMed ID: 38278991
[TBL] [Abstract][Full Text] [Related]
8. TDP-43 and other hnRNPs regulate cryptic exon inclusion of a key ALS/FTD risk gene, UNC13A.
Koike Y; Pickles S; Estades Ayuso V; Jansen-West K; Qi YA; Li Z; Daughrity LM; Yue M; Zhang YJ; Cook CN; Dickson DW; Ward M; Petrucelli L; Prudencio M
PLoS Biol; 2023 Mar; 21(3):e3002028. PubMed ID: 36930682
[TBL] [Abstract][Full Text] [Related]
9. Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers.
Akiyama T; Koike Y; Petrucelli L; Gitler AD
Clin Transl Med; 2022 May; 12(5):e818. PubMed ID: 35567447
[TBL] [Abstract][Full Text] [Related]
10. A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue.
Cao MC; Ryan B; Wu J; Curtis MA; Faull RLM; Dragunow M; Scotter EL
Neurobiol Dis; 2023 Sep; 185():106245. PubMed ID: 37527763
[TBL] [Abstract][Full Text] [Related]
11. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43.
Sun M; Bell W; LaClair KD; Ling JP; Han H; Kageyama Y; Pletnikova O; Troncoso JC; Wong PC; Chen LL
Acta Neuropathol; 2017 Jun; 133(6):923-931. PubMed ID: 28332094
[TBL] [Abstract][Full Text] [Related]
12. The era of cryptic exons: implications for ALS-FTD.
Mehta PR; Brown AL; Ward ME; Fratta P
Mol Neurodegener; 2023 Mar; 18(1):16. PubMed ID: 36922834
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations.
Zhang Z; Almeida S; Lu Y; Nishimura AL; Peng L; Sun D; Wu B; Karydas AM; Tartaglia MC; Fong JC; Miller BL; Farese RV; Moore MJ; Shaw CE; Gao FB
PLoS One; 2013; 8(10):e76055. PubMed ID: 24143176
[TBL] [Abstract][Full Text] [Related]
14. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
[TBL] [Abstract][Full Text] [Related]
15. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain.
Umoh ME; Dammer EB; Dai J; Duong DM; Lah JJ; Levey AI; Gearing M; Glass JD; Seyfried NT
EMBO Mol Med; 2018 Jan; 10(1):48-62. PubMed ID: 29191947
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
Bourbouli M; Rentzos M; Bougea A; Zouvelou V; Constantinides VC; Zaganas I; Evdokimidis I; Kapaki E; Paraskevas GP
Dement Geriatr Cogn Disord; 2017; 44(3-4):144-152. PubMed ID: 28848086
[TBL] [Abstract][Full Text] [Related]
17. Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum.
Shen T; Vogel JW; Duda J; Phillips JS; Cook PA; Gee J; Elman L; Quinn C; Amado DA; Baer M; Massimo L; Grossman M; Irwin DJ; McMillan CT
Transl Neurodegener; 2023 Dec; 12(1):57. PubMed ID: 38062485
[TBL] [Abstract][Full Text] [Related]
18. Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis.
van der Zee J; Dillen L; Baradaran-Heravi Y; Gossye H; Koçoğlu C; Cuyt I; Dermaut B; Sieben A; Baets J; De Jonghe P; Vandenberghe R; De Deyn P; Cras P; Engelborghs S; Van Broeckhoven C;
Neurobiol Dis; 2021 Aug; 156():105421. PubMed ID: 34118419
[TBL] [Abstract][Full Text] [Related]
19. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR; Kalab P
Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
[TBL] [Abstract][Full Text] [Related]
20. Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice.
McCann EP; Fifita JA; Grima N; Galper J; Mehta P; Freckleton SE; Zhang KY; Henden L; Hogan AL; Chan Moi Fat S; Wu SS; Jagaraj CJ; Berning BA; Williams KL; Twine NA; Bauer D; Piguet O; Hodges J; Kwok JBJ; Halliday GM; Kiernan MC; Atkin J; Rowe DB; Nicholson GA; Walker AK; Blair IP; Yang S
J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):162-171. PubMed ID: 31690696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
